8-K: Travere Therapeutics Reports Strong FILSPARI Sales and Provides 2025 Outlook

Travere Therapeutics announced preliminary Q4 2024 net product sales of approximately $74 million and provided updates on key clinical and regulatory milestones.

Summary

• Travere Therapeutics expects approximately $74 million in net product sales for the fourth quarter of 2024.
• The company anticipates full year 2024 net product sales to be around $227 million.
• They ended 2024 with approximately $371 million in cash, cash equivalents, and marketable securities.
• FILSPARI received 693 new patient start forms in Q4 2024, with preliminary net sales of approximately $50 million for the quarter and $132 million for the full year.
• The FDA has accepted for review a supplemental New Drug Application (sNDA) to modify liver monitoring for FILSPARI in IgAN, with a PDUFA target action date of August 28, 2025.
• The company expects to provide a regulatory update on sparsentan in FSGS by its fourth quarter 2024 earnings call.
• A $17.5 million milestone payment is expected from CSL Vifor upon full approval of FILSPARI in Europe.
• The company anticipates restarting enrollment in the Phase 3 HARMONY Study for pegtibatinase in 2026.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with strong sales growth, regulatory progress, and a solid cash position. The company is meeting its milestones and has a clear path forward. There are some risks, but the overall tone is optimistic.

Positives

• FILSPARI sales are showing strong growth, with a 40% increase in Q4 compared to Q3.
• The number of new patient start forms for FILSPARI is increasing, indicating strong market adoption.
• The FDA's acceptance of the sNDA for modified liver monitoring is a positive regulatory development.
• The company is on track with its regulatory and clinical development plans for both IgAN and FSGS.
• The company has a strong cash position of approximately $371 million.
• The company anticipates a milestone payment of $17.5 million from CSL Vifor.

Negatives

• The preliminary financial results are unaudited and subject to change.
• The company is still working on process improvements for manufacturing scale-up of pegtibatinase.
• There is a risk that the FDA may not approve the sNDA for modified liver monitoring.
• There is no guarantee that regulators will grant approval of sparsentan for FSGS.

Risks

• The preliminary financial results are subject to revision based on year-end closing procedures and external audit.
• Actual results may differ materially from the preliminary unaudited results.
• There are risks associated with the ongoing commercial launch of FILSPARI, including market acceptance and competition.
• The timing and outcome of clinical studies and regulatory reviews are uncertain.
• The company faces risks related to manufacturing scale-up and dependence on contractors.
• There are risks associated with global and macroeconomic conditions, including health epidemics and pandemics.
• There is a risk that the company will be unable to raise additional funding that may be required to complete development of any or all of its product candidates.

Future Outlook

The company anticipates continued growth in FILSPARI sales, potential approval of modified liver monitoring, and further development of sparsentan for FSGS. They also expect to restart enrollment in the Phase 3 HARMONY Study in 2026.

Management Comments

• The fourth quarter capped a tremendous year of execution for Travere.
• Following full approval of FILSPARI in September, the ongoing U.S. commercial launch resulted in nearly 700 new patient start forms in the fourth quarter as well as a 40% increase in FILSPARI net product sales compared to the third quarter.
• As we look ahead to the new year, we expect to help even more patients with IgAN through continued strong commercial execution, the final publication of the updated KDIGO guidelines and potential approval of the recently accepted sNDA to modify liver monitoring for FILSPARI.
• Beyond IgAN, we believe that sparsentan has the potential to become an important new medicine for people with FSGS, and we remain on track to provide an update on our interactions with FDA to establish a potential regulatory pathway for this additional indication by our fourth quarter 2024 earnings call.

Industry Context

This announcement highlights the continued commercial success of FILSPARI in the IgAN market and the company's efforts to expand its use to other indications like FSGS. The acceptance of the sNDA for modified liver monitoring is a positive development that could further improve the drug's market position. The launch of FILSPARI in Europe by CSL Vifor also expands the market reach of the drug.

Comparison to Industry Standards

• Travere's 40% quarter-over-quarter growth in FILSPARI sales is a strong indicator of successful commercialization, which is a key metric for pharmaceutical companies launching new drugs.
• The 693 new patient start forms in Q4 2024 suggests a robust adoption rate, which is comparable to or better than other recent launches in the rare disease space.
• The company's cash position of $371 million provides a solid financial foundation for continued operations and development, which is important for a biotech company in the clinical stage.
• The PDUFA date of August 28, 2025, for the sNDA is within the typical timeframe for FDA reviews, indicating a standard regulatory process.
• The expected $17.5 million milestone payment from CSL Vifor is a positive sign of the commercial potential of FILSPARI in Europe, which is a key market for pharmaceutical companies.

Stakeholder Impact

• Shareholders will likely view the strong sales growth and positive regulatory developments favorably.
• Patients with IgAN and FSGS may benefit from the continued development and commercialization of FILSPARI and sparsentan.
• Employees may be motivated by the company's progress and positive outlook.
• The company's partners, such as CSL Vifor and Renalys Pharma, will be impacted by the progress of FILSPARI and sparsentan.

Next Steps

• The company will provide a regulatory update on sparsentan in FSGS by its fourth quarter 2024 earnings call.
• The company anticipates final publication of the updated KDIGO clinical guidelines for IgAN in 2025.
• The company expects to present additional data from its ongoing clinical studies to further support FILSPARI as foundational therapy in treating patients with IgAN in 2025.
• The company and CSL Vifor anticipate the current conditional marketing authorization (CMA) for FILSPARI for the treatment of IgAN in Europe will be converted to full approval in 2025.
• Travere's partner Renalys Pharma, Inc. expects topline results from its registrational Phase 3 clinical trial of sparsentan for the treatment of IgA nephropathy in Japan in the second half of 2025.
• The company expects to announce complete full year 2024 financial results and provide a corporate update in February.
• The company is on track to restart enrollment in the Phase 3 HARMONY Study in 2026.

Key Dates

Keywords

FILSPARI, sparsentan, IgAN, FSGS, Travere Therapeutics, FDA, net product sales, clinical trials, regulatory approval, milestone payment, pegtibatinase, HARMONY Study